Extended Data Table 5 Serious adverse events

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

  1. Safety analysis set included patients who received ≥1 dose of study treatment; includes adverse events (AEs) defined as any AE newly occurring or worsening after the first dose of study treatment to 18 weeks after last dose of study treatment.
  2. Treatment-related AEs by system organ class and preferred term. MedDRA Dictionary (Version 24.0) was used for coding AEs.
  3. GVHD, graft-versus-host disease.
Back to article page